Equibles does not estimate personal net worth.
Get an email with a short summary when Ultragenyx Pharmaceutical Inc. publishes a filing, an earnings call transcript or a press release.
Get RARE alertsEric Crombez, M.D. is recorded as CTO at Ultragenyx Pharmaceutical Inc. (RARE) since May 1, 2023. Ultragenyx Pharmaceutical Inc. reported in an 8-K filed March 14, 2023 that Eric Crombez, M.D. was appointed Executive Vice President, Chief Medical Officer, effective May 1, 2023. Eric Crombez, M.D. has spoken on 1 earnings call across 1 company, most recently for Ultragenyx Pharmaceutical Inc. on May 5, 2026. Ultragenyx Pharmaceutical Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ultragenyx Pharmaceutical Inc. includes Emil D. Kakkis (CEO and Board Member), Emil Kakkis (CEO and Board Member), Howard Horn (CFO) and 7 others.
“Eric Crombez, M.D., the Company's current Chief Medical Officer for Gene Therapy and Inborn Errors of Metabolism, will assume the role of Executive Vice President, Chief Medical Officer, effective as of the Effective Date.”
“As Amal mentioned in the opening, I'll focus on the clinically meaningful Phase 1-2 data that we have generated with GTX-102, are antisense oligonucleotide for the treatment of Angelman syndrome.”
2023-05-01–present
2023-05-01–present
Biotechnology · Healthcare
CTO
2023-05-01–present
